Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-03-18 | Mr. Michael B. MoorePresident | -136,80k | 1,24M | Vente | 8,77 - 9,42 | 1,77M | -7,16% |
| 2026-03-18 | Mr. Michael B. MoorePresident | -136,80k | 1,24M | Vente | 8,77 - 9,42 | 1,77M | -7,16% |
| 2026-01-29 | Mr. Casey HoytCEO & Director | 39,80k | 0,00 | Derivative Exercise and Retained Stock | - | 2,34M | 1,73% |
| 2026-01-29 | Mr. Casey HoytCEO & Director | -13,27k | 99,22k | Derivative Exercise and Sale | 7,48 | 2,34M | - |
| 2026-01-29 | Mr. Casey HoytCEO & Director | -13,91k | 104,07k | Sale to Issuer | 7,48 | 2,34M | -0,59% |
| 2026-01-29 | Mr. William Todd ZehnderCOO & Director | 26,84k | 0,00 | Derivative Exercise and Retained Stock | - | 390,31k | 7,38% |
| 2026-01-29 | Mr. William Todd ZehnderCOO & Director | -8,95k | 66,93k | Derivative Exercise and Sale | 7,48 | 390,31k | - |
| 2026-01-29 | Mr. William Todd ZehnderCOO & Director | -11,37k | 85,03k | Sale to Issuer | 7,48 | 390,31k | -2,83% |
| 2026-01-29 | Mr. Trae Paul FitzgeraldCFO | 9,79k | 0,00 | Derivative Exercise and Retained Stock | - | 105,64k | 10,22% |
| 2026-01-29 | Mr. Trae Paul FitzgeraldCFO | -3,27k | 24,42k | Derivative Exercise and Sale | 7,48 | 105,64k | - |
| 2026-01-29 | Mr. Trae Paul FitzgeraldCFO | -2,68k | 20,04k | Sale to Issuer | 7,48 | 105,64k | -2,47% |
| 2026-01-29 | Mr. Michael B. MoorePresident | 26,84k | 0,00 | Derivative Exercise and Retained Stock | - | 1,91M | 1,42% |
| 2026-01-29 | Mr. Michael B. MoorePresident | -8,95k | 66,92k | Derivative Exercise and Sale | 7,48 | 1,91M | - |
| 2026-01-29 | Mr. Michael B. MoorePresident | -7,34k | 54,92k | Sale to Issuer | 7,48 | 1,91M | -0,38% |
| 2026-01-29 | Dr. William Dana FrazierChief Medical Officer & Director | 2,33k | 0,00 | Derivative Exercise and Retained Stock | - | 73,21k | 3,29% |
| 2026-01-29 | Dr. William Dana FrazierChief Medical Officer & Director | -778,00 | 5,82k | Derivative Exercise and Sale | 7,48 | 73,21k | - |
| 2026-01-29 | Dr. William Dana FrazierChief Medical Officer & Director | -802,00 | 6,00k | Sale to Issuer | 7,48 | 73,21k | -1,08% |
| 2026-01-29 | Mr. Jerome Richard CambreVP of Sales | 8,62k | 0,00 | Derivative Exercise and Retained Stock | - | 104,09k | 9,03% |
| 2026-01-29 | Mr. Jerome Richard CambreVP of Sales | -2,87k | 21,49k | Derivative Exercise and Sale | 7,48 | 104,09k | - |
| 2026-01-29 | Mr. Jerome Richard CambreVP of Sales | -2,36k | 17,62k | Sale to Issuer | 7,48 | 104,09k | -2,21% |
| 2026-01-29 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | 10,77k | 0,00 | Derivative Exercise and Retained Stock | - | 46,49k | 30,16% |
| 2026-01-29 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -3,59k | 26,86k | Derivative Exercise and Sale | 7,48 | 46,49k | - |
| 2026-01-29 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -2,94k | 21,98k | Sale to Issuer | 7,48 | 46,49k | -5,95% |
| 2026-01-21 | Mr. William Todd ZehnderCOO & Director | 117,55k | 0,00 | Derivative Exercise and Retained Stock | - | 374,84k | 45,69% |
| 2026-01-21 | Mr. William Todd ZehnderCOO & Director | -8,55k | 64,07k | Derivative Exercise and Sale | 7,49 | 374,84k | - |
| 2026-01-21 | Mr. William Todd ZehnderCOO & Director | -35,08k | 262,71k | Sale to Issuer | 7,49 | 374,84k | -8,56% |
| 2026-01-21 | Mr. Trae Paul FitzgeraldCFO | 13,32k | 0,00 | Derivative Exercise and Retained Stock | - | 98,52k | 15,63% |
| 2026-01-21 | Mr. Trae Paul FitzgeraldCFO | -3,33k | 24,93k | Derivative Exercise and Sale | 7,49 | 98,52k | - |
| 2026-01-21 | Mr. Trae Paul FitzgeraldCFO | -4,25k | 31,80k | Sale to Issuer | 7,49 | 98,52k | -4,13% |
| 2026-01-21 | Mr. Jerome Richard CambreVP of Sales | 11,72k | 0,00 | Derivative Exercise and Retained Stock | - | 97,82k | 13,61% |
| 2026-01-21 | Mr. Jerome Richard CambreVP of Sales | -2,93k | 21,95k | Derivative Exercise and Sale | 7,49 | 97,82k | - |
| 2026-01-21 | Mr. Jerome Richard CambreVP of Sales | -3,83k | 28,66k | Sale to Issuer | 7,49 | 97,82k | -3,76% |
| 2026-01-21 | Dr. William Dana FrazierChief Medical Officer & Director | 3,40k | 0,00 | Derivative Exercise and Retained Stock | - | 71,68k | 4,98% |
| 2026-01-21 | Dr. William Dana FrazierChief Medical Officer & Director | -850,00 | 6,37k | Derivative Exercise and Sale | 7,49 | 71,68k | - |
| 2026-01-21 | Dr. William Dana FrazierChief Medical Officer & Director | -1,17k | 8,76k | Sale to Issuer | 7,49 | 71,68k | -1,60% |
| 2026-01-21 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | 14,65k | 0,00 | Derivative Exercise and Retained Stock | - | 38,66k | 61,01% |
| 2026-01-21 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -3,66k | 27,43k | Derivative Exercise and Sale | 7,49 | 38,66k | - |
| 2026-01-21 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -4,78k | 35,82k | Sale to Issuer | 7,49 | 38,66k | -11,01% |
| 2026-01-21 | Mr. Michael B. MoorePresident | -9,36k | 70,09k | Sale to Issuer | 7,49 | 1,89M | -0,49% |
| 2026-01-21 | Mr. Michael B. MoorePresident | 34,21k | 0,00 | Derivative Exercise and Retained Stock | - | 1,89M | 1,84% |
| 2026-01-21 | Mr. Michael B. MoorePresident | -8,55k | 64,07k | Derivative Exercise and Sale | 7,49 | 1,89M | - |
| 2026-01-21 | Mr. Casey HoytCEO & Director | 49,60k | 0,00 | Derivative Exercise and Retained Stock | - | 2,31M | 2,19% |
| 2026-01-21 | Mr. Casey HoytCEO & Director | -12,40k | 92,88k | Derivative Exercise and Sale | 7,49 | 2,31M | - |
| 2026-01-21 | Mr. Casey HoytCEO & Director | -13,57k | 101,60k | Sale to Issuer | 7,49 | 2,31M | -0,58% |
| 2026-01-17 | Mr. Michael B. MoorePresident | 26,94k | 0,00 | Derivative Exercise and Retained Stock | - | 1,87M | 1,46% |
| 2026-01-17 | Mr. Michael B. MoorePresident | -6,74k | 49,37k | Derivative Exercise and Sale | 7,33 | 1,87M | - |
| 2026-01-17 | Mr. Michael B. MoorePresident | -8,55k | 62,66k | Sale to Issuer | 7,33 | 1,87M | -0,46% |
| 2026-01-17 | Mr. Casey HoytCEO & Director | 40,07k | 0,00 | Derivative Exercise and Retained Stock | - | 2,27M | 1,79% |
| 2026-01-17 | Mr. Casey HoytCEO & Director | -10,02k | 73,42k | Derivative Exercise and Sale | 7,33 | 2,27M | - |
| 2026-01-17 | Mr. Casey HoytCEO & Director | -12,12k | 88,82k | Sale to Issuer | 7,33 | 2,27M | -0,53% |
| 2026-01-17 | Mr. William Todd ZehnderCOO & Director | 26,94k | 0,00 | Derivative Exercise and Retained Stock | - | 292,36k | 10,15% |
| 2026-01-17 | Mr. William Todd ZehnderCOO & Director | -6,74k | 49,37k | Derivative Exercise and Sale | 7,33 | 292,36k | - |
| 2026-01-17 | Mr. William Todd ZehnderCOO & Director | -8,55k | 62,67k | Sale to Issuer | 7,33 | 292,36k | -2,84% |
| 2026-01-17 | Mr. Trae Paul FitzgeraldCFO | 9,59k | 0,00 | Derivative Exercise and Retained Stock | - | 89,45k | 12,01% |
| 2026-01-17 | Mr. Trae Paul FitzgeraldCFO | -2,40k | 17,57k | Derivative Exercise and Sale | 7,33 | 89,45k | - |
| 2026-01-17 | Mr. Trae Paul FitzgeraldCFO | -3,13k | 22,96k | Sale to Issuer | 7,33 | 89,45k | -3,38% |
| 2026-01-17 | Mr. Jerome Richard CambreVP of Sales | 8,53k | 0,00 | Derivative Exercise and Retained Stock | - | 89,93k | 10,47% |
| 2026-01-17 | Mr. Jerome Richard CambreVP of Sales | -2,13k | 15,63k | Derivative Exercise and Sale | 7,33 | 89,93k | - |
| 2026-01-17 | Mr. Jerome Richard CambreVP of Sales | -2,78k | 20,41k | Sale to Issuer | 7,33 | 89,93k | -3,00% |
| 2026-01-17 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | 4,88k | 0,00 | Derivative Exercise and Retained Stock | - | 28,79k | 20,43% |
| 2026-01-17 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -1,22k | 8,95k | Derivative Exercise and Sale | 7,33 | 28,79k | - |
| 2026-01-17 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -1,60k | 11,69k | Sale to Issuer | 7,33 | 28,79k | -5,25% |
| 2025-08-22 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | 5,97k | 0,00 | Derivative Exercise and Retained Stock | - | 25,50k | 30,57% |
| 2025-08-22 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -2,99k | 21,83k | Derivative Exercise and Sale | 7,31 | 25,50k | - |
| 2025-08-22 | Mr. Jeremy TrahanGeneral Counsel & Corporate Secretary | -1,63k | 11,94k | Sale to Issuer | 7,31 | 25,50k | -6,02% |
| 2025-08-20 | Mr. Nitin KaushalIndependent Director | 15,73k | 0,00 | Derivative Exercise and Retained Stock | - | 142,58k | 12,40% |
| 2025-08-20 | Mr. Timothy SmokoffIndependent Director | 15,73k | 0,00 | Derivative Exercise and Retained Stock | - | 95,52k | 19,72% |
| 2025-08-20 | Mr. Randolph E. DobbsIndependent Chairman | 17,78k | 0,00 | Derivative Exercise and Retained Stock | - | 125,49k | 16,51% |
| 2025-08-20 | Ms. Sabrina HeltzIndependent Director | 15,73k | 0,00 | Derivative Exercise and Retained Stock | - | 67,49k | 30,39% |
| 2025-08-13 | Mr. Jerome Richard CambreVP of Sales | -4,88k | 35,74k | Vente | 7,32 - 7,33 | 84,19k | -5,48% |
| 2025-08-12 | Mr. Michael B. MoorePresident | -50,09k | 367,16k | Vente | 7,33 | 1,85M | -2,64% |
| 2025-01-29 | Mr. Michael B. MoorePresident | -8,95k | 74,09k | Sale to Issuer | 8,28 | 1,90M | -0,47% |
| 2025-06-27 | Mr. Michael B. MoorePresident | -181,32k | 809,51k | Derivative Exercise and Sale | 1,81 - 7,00 | 1,90M | - |
| 2025-06-30 | Mr. Nitin KaushalIndependent Director | -7,05k | 1,97k | Derivative Exercise and Sale | 6,63 - 6,91 | 126,84k | - |
| 2025-06-26 | Mr. Nitin KaushalIndependent Director | -42,95k | 16,23k | Derivative Exercise and Sale | 6,63 - 7,01 | 126,84k | - |
| 2025-06-26 | Mr. Nitin KaushalIndependent Director | -42,95k | 16,23k | Derivative Exercise and Sale | 6,63 - 7,01 | 126,84k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
